middle.news
Biotron finds strong antiviral activity as SedRx moves toward European trial planning
10:32am on Wednesday 28th of October, 2026 AEDT
•
Biotechnology
Read Story
Biotron finds strong antiviral activity as SedRx moves toward European trial planning
10:32am on Wednesday 28th of October, 2026 AEDT
Key Points
99.7% reduction in HBV-DNA in cell-based testing
Significant synergy with Myrcludex B across three replication endpoints
Updated EMA submission for SedRx regulatory advice underway
A$1.06 million cash balance and 2.15-quarter funding estimate
Read Story
middle.
Tap to Read
Tap the card to read the full analysis
about
Biotron (ASX:BIT)
OPEN ARTICLE